A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation

MC #23-16

A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation

NCT #
NCT06039384
Condition(s)
Colorectal, Non-Small Cell Lung, Solid Tumors
Molecular Target(s)
PD-L1
Drug Classification(s)
Small Molecule Immunotherapy
Agents(s)
INCB099280
Phase(s)
I

Mechanism of Action

INCB099280 is a PD-L1 inhibitor. Adagrasib is a KRAS inhibitor (G12C).

Purpose

  • How much of the study s can be given with an acceptable level of side effects
  • The effects of the study s (good and bad)
  • How much of the study s are absorbed into the blood and how fast they are removed
  • How the study s are acting on your body

Location

MCD

Connect With Us

Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.